Literature DB >> 15611064

Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.

Felicia Miller1, Alex Kentsis, Roman Osman, Zhen-Qiang Pan.   

Abstract

The von Hippel-Lindau (VHL) gene product, pVHL, targets the alpha subunit of the hypoxia-inducible transcription factor (HIF-alpha) for ubiquitin-dependent degradation. This tumor suppressor function is mediated by the alpha- and beta-domains responsible for assembling the pVHL E3 ubiquitin ligase complex and for recognizing the prolyl-hydroxylated HIF-alpha, respectively. The molecular basis for a large number of tumor-derived mutations can be attributed to alterations that directly compromise the ability of pVHL to assemble the E3 or to contact the substrate. Here we describe a new mechanism of oncogenic inactivation by VHL missense mutations that lie in the L1 and L7 linker regions distal to the HIF-alpha-binding pocket. Employing molecular dynamics simulations, we show that the tumorigenic L1 loop mutation of Ser(65) to Leu, deficient in promoting the degradation of HIF-alpha, disrupts the coordination of internal motions of the pVHL.HIF-1alpha complex. Furthermore, we demonstrate that in addition to S65L, five other tumor-derived VHL mutations located within the L1 loop are each defective in mediating proteolysis of HIF-2alpha. Moreover, dynamic organization of pVHL.HIF-1alpha recognition is focally centered on Gln(145) within the L7 loop, and its tumorigenic mutant Q145H abolishes almost all of the correlated dynamic motions. Intriguingly, Q145H, whereas defective in targeting cellular HIF-alpha for degradation, had an attenuated hydroxylation dependence in binding to HIF-1alpha in vitro. Taken together, our results suggest that specific association between pVHL and the hydroxylated HIF-alpha requires both the L1 and L7 loops to coordinate dynamic coupling among distant pVHL regions, whose mutational disruption inactivates VHL and is hence responsible for tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15611064     DOI: 10.1074/jbc.M413160200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Transcriptional profiling of CD133(+) cells in coronary artery disease and effects of exercise on gene expression.

Authors:  Delong Liu; Alexander P Glaser; Sushmitha Patibandla; Arnon Blum; Peter J Munson; J Philip McCoy; Nalini Raghavachari; Richard O Cannon
Journal:  Cytotherapy       Date:  2011-02       Impact factor: 5.414

2.  Arginine refolds, stabilizes, and restores function of mutant pVHL proteins in animal model of the VHL cancer syndrome.

Authors:  Merav D Shmueli; Limor Levy-Kanfo; Esraa Haj; Alan R Schoenfeld; Ehud Gazit; Daniel Segal
Journal:  Oncogene       Date:  2018-09-07       Impact factor: 9.867

3.  VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma.

Authors:  Jing Zhang; Tao Wu; Jeremy Simon; Mamoru Takada; Ryoichi Saito; Cheng Fan; Xian-De Liu; Eric Jonasch; Ling Xie; Xian Chen; Xiaosai Yao; Bin Tean Teh; Patrick Tan; Xingnan Zheng; Mingjie Li; Cortney Lawrence; Jie Fan; Jiang Geng; Xijuan Liu; Lianxin Hu; Jun Wang; Chengheng Liao; Kai Hong; Giada Zurlo; Joel S Parker; J Todd Auman; Charles M Perou; W Kimryn Rathmell; William Y Kim; Marc W Kirschner; William G Kaelin; Albert S Baldwin; Qing Zhang
Journal:  Science       Date:  2018-07-20       Impact factor: 47.728

4.  A novel germline mutation of the VHL gene in a Greek family with Von Hippel-Lindau disease.

Authors:  Melpomeni Peppa; Smaragda Kamakari; Eleni Boutati; Panagiotis Nikolopoulos; Christoforos Giatzakis; Theofanis Economopoulos; Dimitrios Hadjidakis; Sotirios A Raptis
Journal:  BMJ Case Rep       Date:  2009-08-19

5.  Genotype-phenotype analysis of von Hippel-Lindau syndrome in fifteen Indian families.

Authors:  Narendranath Vikkath; Sindhu Valiyaveedan; Sheela Nampoothiri; Natasha Radhakrishnan; Gopal S Pillai; Vasantha Nair; Ginil Kumar Pooleri; Georgie Mathew; Krishnakumar N Menon; Prasanth S Ariyannur; Ashok B Pillai
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

6.  Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.

Authors:  Á Ordóñez-Navadijo; E Fuertes-Yebra; B Acosta-Iborra; E Balsa; A Elorza; J Aragonés; M O Landazuri
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

7.  The von Hippel-Lindau tumor suppressor protein and Egl-9-Type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress.

Authors:  Olga Mikhaylova; Monika L Ignacak; Teresa J Barankiewicz; Svetlana V Harbaugh; Ying Yi; Patrick H Maxwell; Martin Schneider; Katie Van Geyte; Peter Carmeliet; Monica P Revelo; Michael Wyder; Kenneth D Greis; Jarek Meller; Maria F Czyzyk-Krzeska
Journal:  Mol Cell Biol       Date:  2008-02-19       Impact factor: 4.272

Review 8.  The role of HIF1α in renal cell carcinoma tumorigenesis.

Authors:  Lorraine J Gudas; Leiping Fu; Denise R Minton; Nigel P Mongan; David M Nanus
Journal:  J Mol Med (Berl)       Date:  2014-06-12       Impact factor: 4.599

9.  Human Cdc34 employs distinct sites to coordinate attachment of ubiquitin to a substrate and assembly of polyubiquitin chains.

Authors:  Stefan Gazdoiu; Kosj Yamoah; Kenneth Wu; Zhen-Qiang Pan
Journal:  Mol Cell Biol       Date:  2007-08-13       Impact factor: 4.272

10.  Germline mutation of Glu70Lys is highly frequent in Korean patients with von Hippel-Lindau (VHL) disease.

Authors:  Sena Hwang; Cheol Ryong Ku; Ji In Lee; Kyu Yeon Hur; Myung-Shik Lee; Chul-Ho Lee; Kyo Yeon Koo; Jin-Sung Lee; Yumie Rhee
Journal:  J Hum Genet       Date:  2014-07-31       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.